Alexandria Real Estate Equities, Inc. (ARE)
Bienes raíces / REIT de ciencias de la vida
Alexandria is the pioneering and largest-scale REIT in life sciences real estate (Megacampus platform, 92% triple-net contracts), but faces a genuine oversupply crisis: occupancy falling three consecutive periods (94.6%→90.9%→86.9%), adjusted FFO guidance -29% for 2026 (US$6.40), and dividend already cut 45%. At $53 (7× adjusted FFO, well below the normal REIT band) the market is already pricing in a crisis: Very undervalued, with a base value of $101 (+18%) that requires the deleveraging plan and occupancy stabilization to be executed.
- Price
- $53.22
- Intrinsic value (5y, base)
- $101
- Total annual return (5y)
- 18.0%
- Status (nominal)
- Very undervalued
- Margin of safety
- +43%
The essentials
- The pioneering REIT (since 1994) and largest-scale operator in life sciences real estate: 340 properties, ~39.4 million rentable square feet across innovation clusters (Boston, San Francisco Bay Area, San Diego, among others), 92% triple-net contracts and 97% with annual rent escalations of ~3%.
- Faces a genuine oversupply crisis, not just market perception: laboratory availability in the three principal markets rose from ~4% (2021) to ~29% (today); occupancy declined from 94.6% (2024) to 90.9% (2025) and 86.9% (2Q26), and the company recognized US$2.20bn in real estate impairments in 2025.
- The dividend was cut 45% (from US$1.32 to US$0.72 quarterly) since 4Q25 and adjusted FFO per share guidance for 2026 is US$6.40 (midpoint), a -29% decline versus 2025's US$9.01 — management prioritizes deleveraging (5.6-6.2× target by end of 2026) over dividend growth.
Intrinsic value — two valuation methods
Total return at 5 years: 18.0%/year = 13.7% appreciation + 4.3% dividend. The target price ($101) is ex-dividend; the $14 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $75 · Multiples $94) exceeds the market price ($53).
Pillars of the analysis
The verdict — today vs 5 years
Today — with margin of safety: at $53 trades ~43.2% below its value discounted to today (~$94) — the wide discount we require (≥38%, equivalent to a ~15% annual return); the risk is covered by the margin, not the rate.
At 5 years — Muy infravalorado: the target price ($101) plus dividends yield above the required average return (10%) — the business compounds.
The bridge: the return at 5 years comfortably exceeds the risk-free rate (4.5%) — and the discount reaches the required margin of safety.
Thesis
The business
Alexandria is the longest-tenured and largest-scale life sciences real estate REIT, with Megacampus locations difficult to replicate, triple-net contracts with contractual escalations, and a high-quality tenant base. Yet the business faces a genuine sectoral oversupply crisis — not merely a multiple contraction — with occupancy falling, renewal rents projected negative in 2026 guidance, and US$2.20bn in real estate impairments already recognized in 2025.
The valuation
A REIT is valued by adjusted FFO per share (equivalent to P/Core-FFO), not by P/E — real estate depreciation is not an economic cost. ARE guides adjusted FFO per share of US$6.40 (midpoint) for 2026, -29% versus 2025's US$9.01. At $53 it trades at 7× adjusted FFO — well below the method's reference REIT band (15-20×). The base case assumes a floor around 2026-2027 and gradual recovery from year 3 (contingent on the US$2.9bn disposition program and occupancy stabilization) toward ~US$6.75 adjusted FFO per share by year 5, with the multiple normalizing partially toward the band floor (15×, from 13× at 3 years). That yields $101/share → +18% total return.
The margin of safety
There is a margin of safety: the market's perception is meaningfully worse than reality. The base return (+18% total: +14%/year from price and +4% from dividends) relies almost entirely on multiple re-rating (from ~7-8× today to 15× by year 5) plus moderate operational recovery — not today's business. That re-rating is conditional: it depends on the US$2.9bn disposition program executing as guided and occupancy stabilizing within the 86.2%-87.8% range guided for end of 2026. The Very undervalued verdict reflects that asymmetry: if the plan is executed, the margin is real; if not, the market's discount is justified and no real margin exists.
What to watch
The central disconfirmation is twofold: (1) that leverage (7.0× net debt/adjusted EBITDA at 2Q26) does not decline toward the 5.6-6.2× target by end of 2026 because the US$2.9bn disposition program executes at values below expectations; and (2) that occupancy continues to fall below the 86.2% floor guided for end of 2026, signaling that oversupply (~29% availability in the three principal markets) takes longer than modeled to absorb. The US$2.20bn in impairments already recognized in 2025 is evidence that part of this decline is real value loss, not merely market perception.
Educational / informational. Does not constitute investment advice.